Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Praxis Precision Medicines appoints Tim Kelly as Chief Financial Officer » 08:06
05/25/21
05/25
08:06
05/25/21
08:06
PRAX

Praxis Precision Medicines

$19.35 /

-0.27 (-1.38%)

Praxis Precision…

Praxis Precision Medicines announced the appointment of Tim Kelly as chief financial officer, effective immediately. Kelly joins Praxis from Foundation Medicine, where he served as chief financial officer and head of corporate management. Kelly brings more than 20 years of experience in the life sciences, pharmaceutical and biotechnology industries.

ShowHide Related Items >><<
PRAX Praxis Precision Medicines
$19.35 /

-0.27 (-1.38%)

PRAX Praxis Precision Medicines
$19.35 /

-0.27 (-1.38%)

04/26/21 William Blair
Praxis Precision Medicines initiated with an Outperform at William Blair
04/16/21 Piper Sandler
Praxis Precision Medicines transferred with Overweight at Piper Sandler
03/17/21 Piper Sandler
Piper sees 114 IND, pivotal trial as sign of Praxis regulatory capabilities
01/21/21 Wedbush
Praxis Precision Medicines price target raised to $61 from $51 at Wedbush
PRAX Praxis Precision Medicines
$19.35 /

-0.27 (-1.38%)

  • 14
    May
  • 16
    Oct
PRAX Praxis Precision Medicines
$19.35 /

-0.27 (-1.38%)

Over a month ago
Conference/Events
Oppenheimer to hold a virtual summit » 09:38
05/21/21
05/21
09:38
05/21/21
09:38
BMRN

BioMarin

$79.16 /

+2.83 (+3.71%)

, CATB

Catabasis Pharmaceuticals

$1.95 /

+0.07 (+3.72%)

, CERC

Cerecor

$2.70 /

+0.11 (+4.25%)

, CLRB

Cellectar Biosciences

$1.46 /

-0.02 (-1.35%)

, CMMB

Chemomab Therapeutics

$19.13 /

+0.28 (+1.49%)

, CRBP

Corbus Pharmaceuticals

$1.71 /

+0.095 (+5.88%)

, DCTH

Delcath Systems

$10.46 /

+ (+0.00%)

, ELOX

Eloxx Pharmaceuticals

$1.59 /

+0.12 (+8.16%)

, MGTX

MeiraGTx

$13.10 /

+0.35 (+2.75%)

, MITO

Stealth Biotherapeutics

$1.29 /

-0.035 (-2.64%)

, PRAX

Praxis Precision Medicines

$20.00 /

+0.21 (+1.06%)

, SBBP

Strongbridge Biopharma

$2.33 /

+0.03 (+1.30%)

, SLNO

Soleno Therapeutics

$1.01 /

+0.0058 (+0.58%)

, SVRA

Savara

$1.60 /

-0.05 (-3.03%)

, TARA

Protara Therapeutics

$9.40 /

+0.24 (+2.62%)

Rare & Orphan Disease…

Rare & Orphan Disease Virtual Summit to be held on May 21.

ShowHide Related Items >><<
TARA Protara Therapeutics
$9.40 /

+0.24 (+2.62%)

SVRA Savara
$1.60 /

-0.05 (-3.03%)

SLNO Soleno Therapeutics
$1.01 /

+0.0058 (+0.58%)

SBBP Strongbridge Biopharma
$2.33 /

+0.03 (+1.30%)

PRAX Praxis Precision Medicines
$20.00 /

+0.21 (+1.06%)

MITO Stealth Biotherapeutics
$1.29 /

-0.035 (-2.64%)

MGTX MeiraGTx
$13.10 /

+0.35 (+2.75%)

ELOX Eloxx Pharmaceuticals
$1.59 /

+0.12 (+8.16%)

DCTH Delcath Systems
$10.46 /

+ (+0.00%)

CRBP Corbus Pharmaceuticals
$1.71 /

+0.095 (+5.88%)

CMMB Chemomab Therapeutics
$19.13 /

+0.28 (+1.49%)

CLRB Cellectar Biosciences
$1.46 /

-0.02 (-1.35%)

CERC Cerecor
$2.70 /

+0.11 (+4.25%)

CATB Catabasis Pharmaceuticals
$1.95 /

+0.07 (+3.72%)

BMRN BioMarin
$79.16 /

+2.83 (+3.71%)

BMRN BioMarin
$79.16 /

+2.83 (+3.71%)

04/30/21 Wedbush
BioMarin's Q1 revenue was better than expected, says Wedbush
04/26/21 Credit Suisse
BioMarin assumed with an Outperform at Credit Suisse
03/04/21 Guggenheim
BioMarin assumed at Buy from Neutral at Guggenheim
03/01/21 Evercore ISI
BioMarin upgraded to Outperform from In Line at Evercore ISI
CATB Catabasis Pharmaceuticals
$1.95 /

+0.07 (+3.72%)

05/12/21 Ladenburg
Ladenburg starts Catabasis Pharmaceuticals at Buy with $6 price target
05/12/21 Ladenburg
Catabasis Pharmaceuticals initiated with a Buy at Ladenburg
03/11/21 Oppenheimer
Catabasis Pharmaceuticals upgraded to Outperform at Oppenheimer
03/11/21 Oppenheimer
Catabasis upgraded to Outperform from Perform at Oppenheimer
CERC Cerecor
$2.70 /

+0.11 (+4.25%)

04/21/21 Maxim
Cerecor upgraded to Buy from Hold at Maxim
04/21/21 Maxim
Cerecor upgraded to Buy from Hold at Maxim
04/20/21 Jefferies
Cerecor initiated with a Buy at Jefferies
CLRB Cellectar Biosciences
$1.46 /

-0.02 (-1.35%)

04/27/21 Roth Capital
Cellectar strengthens IP estate as CLR 131 trial progresses, says Roth Capital
07/01/20 Oppenheimer
Oppenheimer bullish on Cellectar Biosciences, initiates with an Outperform
07/01/20 Oppenheimer
Cellectar Biosciences initiated with an Outperform at Oppenheimer
06/23/20
Fly Intel: Top five analyst initiations
CMMB Chemomab Therapeutics
$19.13 /

+0.28 (+1.49%)

05/07/21 Oppenheimer
Chemomab Therapeutics initiated with an Outperform at Oppenheimer
CRBP Corbus Pharmaceuticals
$1.71 /

+0.095 (+5.88%)

10/08/20 H.C. Wainwright
Corbus Pharmaceuticals price target lowered to $3 from $6 at H.C. Wainwright
10/06/20 Roth Capital
Corbus Pharmaceuticals price target lowered to $1.22 from $3 at Roth Capital
09/08/20 Jefferies
Corbus Pharmaceuticals downgraded to Hold from Buy at Jefferies
09/08/20 Oppenheimer
Corbus Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
DCTH Delcath Systems
$10.46 /

+ (+0.00%)

04/06/21 Roth Capital
Delcath Systems price target raised to $25 from $20 at Roth Capital
03/09/21 Canaccord
Delcath Systems initiated with a Buy, $24 target at Canaccord
03/09/21 Canaccord
Delcath Systems initiated with a Buy at Canaccord
01/05/21
BTIG starts Delcath Systems at Buy, sees 'compelling' FOCUS trial data
ELOX Eloxx Pharmaceuticals
$1.59 /

+0.12 (+8.16%)

05/19/21 Piper Sandler
Eloxx Pharmaceuticals price target lowered to $4 from $6 at Piper Sandler
04/01/21 Piper Sandler
Eloxx Pharmaceuticals acquires Zikani in all-stock deal, says Piper Sandler
06/17/20 Piper Sandler
Piper Sandler backs Overweight on Eloxx as cystic fibrosis trials resume
06/11/20
Fly Intel: Top five analyst downgrades
MGTX MeiraGTx
$13.10 /

+0.35 (+2.75%)

04/28/21 Piper Sandler
MeiraGTx should be bought into the $40 range, says Piper Sandler
02/16/21 Chardan
MeiraGTx called a Top Pick for 2021 at Chardan
12/17/20 Chardan
Chardan boosts MeiraGTx target to $55, say buy shares 'now'
12/17/20 Piper Sandler
Piper says MeiraGTx not getting credit for RIX gene therapy that 'clearly works'
MITO Stealth Biotherapeutics
$1.29 /

-0.035 (-2.64%)

PRAX Praxis Precision Medicines
$20.00 /

+0.21 (+1.06%)

04/26/21 William Blair
Praxis Precision Medicines initiated with an Outperform at William Blair
04/16/21 Piper Sandler
Praxis Precision Medicines transferred with Overweight at Piper Sandler
03/17/21 Piper Sandler
Piper sees 114 IND, pivotal trial as sign of Praxis regulatory capabilities
01/21/21 Wedbush
Praxis Precision Medicines price target raised to $61 from $51 at Wedbush
SBBP Strongbridge Biopharma
$2.33 /

+0.03 (+1.30%)

09/08/20 JMP Securities
Weakness in Strongbridge Biopharma 'a buying opportunity,' says JMP Securities
SLNO Soleno Therapeutics
$1.01 /

+0.0058 (+0.58%)

09/29/20 Guggenheim
Soleno Therapeutics initiated with a Buy at Guggenheim
SVRA Savara
$1.60 /

-0.05 (-3.03%)

04/19/21 Piper Sandler
Savara shares are trading below cash, says Piper Sandler
03/16/21
Fly Intel: Top five analyst initiations
03/16/21 Piper Sandler
Savara initiated with an Overweight at Piper Sandler
03/15/21 Oppenheimer
Savara initiated with an Outperform at Oppenheimer
TARA Protara Therapeutics
$9.40 /

+0.24 (+2.62%)

04/26/21 Oppenheimer
Protara Therapeutics price target lowered to $32 from $43 at Oppenheimer
10/19/20 Cowen
Protara Therapeutics initiated with an Outperform at Cowen
07/29/20
Fly Intel: Top five analyst initiations
07/29/20 Guggenheim
Protara Therapeutics started with Buy rating, $50 target at Guggenheim
TARA Protara Therapeutics
$9.40 /

+0.24 (+2.62%)

SVRA Savara
$1.60 /

-0.05 (-3.03%)

SLNO Soleno Therapeutics
$1.01 /

+0.0058 (+0.58%)

SBBP Strongbridge Biopharma
$2.33 /

+0.03 (+1.30%)

PRAX Praxis Precision Medicines
$20.00 /

+0.21 (+1.06%)

MITO Stealth Biotherapeutics
$1.29 /

-0.035 (-2.64%)

MGTX MeiraGTx
$13.10 /

+0.35 (+2.75%)

DCTH Delcath Systems
$10.46 /

+ (+0.00%)

CRBP Corbus Pharmaceuticals
$1.71 /

+0.095 (+5.88%)

CLRB Cellectar Biosciences
$1.46 /

-0.02 (-1.35%)

CERC Cerecor
$2.70 /

+0.11 (+4.25%)

CATB Catabasis Pharmaceuticals
$1.95 /

+0.07 (+3.72%)

BMRN BioMarin
$79.16 /

+2.83 (+3.71%)

  • 14
    May
  • 14
    May
  • 11
    Mar
  • 08
    Jan
  • 23
    Dec
  • 09
    Dec
  • 19
    Nov
  • 16
    Oct
  • 22
    Sep
  • 17
    Sep
  • 24
    Jun
  • 09
    Jun
BMRN BioMarin
$79.16 /

+2.83 (+3.71%)

DCTH Delcath Systems
$10.46 /

+ (+0.00%)

CMMB Chemomab Therapeutics
$19.13 /

+0.28 (+1.49%)

CERC Cerecor
$2.70 /

+0.11 (+4.25%)

BMRN BioMarin
$79.16 /

+2.83 (+3.71%)

TARA Protara Therapeutics
$9.40 /

+0.24 (+2.62%)

SVRA Savara
$1.60 /

-0.05 (-3.03%)

PRAX Praxis Precision Medicines
$20.00 /

+0.21 (+1.06%)

CATB Catabasis Pharmaceuticals
$1.95 /

+0.07 (+3.72%)

Syndicate
Praxis Precision Medicines 5M share Secondary priced at $18.25 » 06:09
05/14/21
05/14
06:09
05/14/21
06:09
PRAX

Praxis Precision Medicines

$18.80 /

-2.81 (-13.00%)

The deal size was…

The deal size was increased to 5M shares from 4M shares. BofA, Cowen, Piper Sandler and Wedbush acted as joint book running managers for the offering.

ShowHide Related Items >><<
PRAX Praxis Precision Medicines
$18.80 /

-2.81 (-13.00%)

PRAX Praxis Precision Medicines
$18.80 /

-2.81 (-13.00%)

04/26/21 William Blair
Praxis Precision Medicines initiated with an Outperform at William Blair
04/16/21 Piper Sandler
Praxis Precision Medicines transferred with Overweight at Piper Sandler
03/17/21 Piper Sandler
Piper sees 114 IND, pivotal trial as sign of Praxis regulatory capabilities
01/21/21 Wedbush
Praxis Precision Medicines price target raised to $61 from $51 at Wedbush
PRAX Praxis Precision Medicines
$18.80 /

-2.81 (-13.00%)

  • 14
    May
  • 16
    Oct
PRAX Praxis Precision Medicines
$18.80 /

-2.81 (-13.00%)

Syndicate
Praxis Precision Medicines announces 4M share common stock offering » 16:24
05/11/21
05/11
16:24
05/11/21
16:24
PRAX

Praxis Precision Medicines

$25.71 /

-0.08 (-0.31%)

Praxis Precision…

Praxis Precision Medicines announced that it has commenced an underwritten public offering of 4M shares of its common stock. Praxis intends to use the net proceeds from the offering, together with its existing cash, cash equivalents and short-term investments, to (i) advance PRAX-114 into and through the completion of the Phase 2/3 Aria Study in monotherapy major depressive disorder, which is intended to satisfy one of two registrational trials required by the FDA to support clinical efficacy for monotherapy MDD, advance PRAX-114 into and through the completion of Praxis' Phase 2 trial for the adjunctive treatment of MDD, complete Part B of the Phase 2a clinical trial for PRAX-114, initiate a Phase 3 monotherapy trial in MDD, initiate and complete a Phase 2 trial in PTSD, initiate and complete a Phase 2 trial in essential tremor and pursue the development of PRAX-114 in an additional indication; (ii) complete its ongoing Phase 2a clinical trial and a Phase 2 randomized, controlled clinical trial for PRAX-944 in ET and initiate and complete a Phase 2 trial of PRAX-944 in Parkinson's Disease; (iii) complete its ongoing PRAX-562 Phase 1 healthy volunteer trial and initiate and complete Phase 2 trials of PRAX-562 in Short-lasting Unilateral Neuralgiform headache attacks with Conjunctival injection and Tearing, Short-lasting Unilateral Neuralgiform headache with Autonomic symptoms, and Trigeminal Neuralgia, and in developmental epileptic encephalopathies, including SCN8A-DEE and SCN2A-DEE and (iv) advance other programs in its pipeline and support working capital and other general corporate purposes.BofA Securities, Cowen and Piper Sandler are acting as joint bookrunning managers for the offering, and Wedbush PacGrow is acting as lead manager for the offering.

ShowHide Related Items >><<
PRAX Praxis Precision Medicines
$25.71 /

-0.08 (-0.31%)

PRAX Praxis Precision Medicines
$25.71 /

-0.08 (-0.31%)

04/26/21 William Blair
Praxis Precision Medicines initiated with an Outperform at William Blair
04/16/21 Piper Sandler
Praxis Precision Medicines transferred with Overweight at Piper Sandler
03/17/21 Piper Sandler
Piper sees 114 IND, pivotal trial as sign of Praxis regulatory capabilities
01/21/21 Wedbush
Praxis Precision Medicines price target raised to $61 from $51 at Wedbush
PRAX Praxis Precision Medicines
$25.71 /

-0.08 (-0.31%)

  • 16
    Oct
PRAX Praxis Precision Medicines
$25.71 /

-0.08 (-0.31%)

Syndicate
Praxis Precision Medicines files to sell 4M shares of common stock  16:19
05/11/21
05/11
16:19
05/11/21
16:19
PRAX

Praxis Precision Medicines

$25.71 /

-0.08 (-0.31%)

 
ShowHide Related Items >><<
PRAX Praxis Precision Medicines
$25.71 /

-0.08 (-0.31%)

PRAX Praxis Precision Medicines
$25.71 /

-0.08 (-0.31%)

04/26/21 William Blair
Praxis Precision Medicines initiated with an Outperform at William Blair
04/16/21 Piper Sandler
Praxis Precision Medicines transferred with Overweight at Piper Sandler
03/17/21 Piper Sandler
Piper sees 114 IND, pivotal trial as sign of Praxis regulatory capabilities
01/21/21 Wedbush
Praxis Precision Medicines price target raised to $61 from $51 at Wedbush
PRAX Praxis Precision Medicines
$25.71 /

-0.08 (-0.31%)

  • 16
    Oct
PRAX Praxis Precision Medicines
$25.71 /

-0.08 (-0.31%)

Hot Stocks
Praxis Precision Medicines expects cash to fund operations into 4Q22 » 08:07
05/11/21
05/11
08:07
05/11/21
08:07
PRAX

Praxis Precision Medicines

$25.79 /

-2.15 (-7.70%)

As of March 31, 2021,…

As of March 31, 2021, Praxis had $270.8 million in cash, cash equivalents and marketable securities, compared to $296.6 million in cash and cash equivalents as of December 31, 2020. This decrease of $25.8 million primarily reflects cash used in operations. The company's cash, cash equivalents and marketable securities as of March 31, 2021 are expected to fund operations into the fourth quarter of 2022.

ShowHide Related Items >><<
PRAX Praxis Precision Medicines
$25.79 /

-2.15 (-7.70%)

PRAX Praxis Precision Medicines
$25.79 /

-2.15 (-7.70%)

04/26/21 William Blair
Praxis Precision Medicines initiated with an Outperform at William Blair
04/16/21 Piper Sandler
Praxis Precision Medicines transferred with Overweight at Piper Sandler
03/17/21 Piper Sandler
Piper sees 114 IND, pivotal trial as sign of Praxis regulatory capabilities
01/21/21 Wedbush
Praxis Precision Medicines price target raised to $61 from $51 at Wedbush
PRAX Praxis Precision Medicines
$25.79 /

-2.15 (-7.70%)

  • 16
    Oct
PRAX Praxis Precision Medicines
$25.79 /

-2.15 (-7.70%)

Earnings
Praxis Precision Medicines reports Q1 EPS (71c), consensus (74c) » 08:07
05/11/21
05/11
08:07
05/11/21
08:07
PRAX

Praxis Precision Medicines

$25.79 /

-2.15 (-7.70%)

"I'm inspired…

"I'm inspired by our team's continued execution and the progress throughout our pipeline during the first quarter, with key milestones achieved across each of our programs. As the pipeline advances, our conviction in our programs continues to grow," said Marcio Souza, president and chief executive officer of Praxis. "In addition to the ongoing enrollment in our PRAX-114 Phase 2/3 Aria study for monotherapy MDD, we are excited to announce the expansion of PRAX-114 into post-traumatic stress disorder and essential tremor, as well as the expansion of PRAX-944 into Parkinson's disease. These disorders all have significant unmet need, as well as both genetic and mechanistic linkage to the respective targets and programs. We believe that Praxis' foundational approach to identifying targets through human genetics, the extensive use of translational tools to inform development and always keeping patient needs top of mind have been instrumental in developing a deep pipeline of CNS programs with considerable optionality."

ShowHide Related Items >><<
PRAX Praxis Precision Medicines
$25.79 /

-2.15 (-7.70%)

PRAX Praxis Precision Medicines
$25.79 /

-2.15 (-7.70%)

04/26/21 William Blair
Praxis Precision Medicines initiated with an Outperform at William Blair
04/16/21 Piper Sandler
Praxis Precision Medicines transferred with Overweight at Piper Sandler
03/17/21 Piper Sandler
Piper sees 114 IND, pivotal trial as sign of Praxis regulatory capabilities
01/21/21 Wedbush
Praxis Precision Medicines price target raised to $61 from $51 at Wedbush
PRAX Praxis Precision Medicines
$25.79 /

-2.15 (-7.70%)

  • 16
    Oct
PRAX Praxis Precision Medicines
$25.79 /

-2.15 (-7.70%)

Hot Stocks
Praxis Precision Medicines receives orphan drug designation for PRAX-562 » 09:02
04/30/21
04/30
09:02
04/30/21
09:02
PRAX

Praxis Precision Medicines

$32.15 /

+0.32 (+1.01%)

Praxis Precision…

Praxis Precision Medicines announced that the Food and Drug Administration has granted orphan drug designation to PRAX-562 for the treatment of SCN2A development and epileptic encephalopathy. PRAX-562 is a small molecule and is the first selective persistent sodium current blocker in development for the treatment of a wide range of rare CNS disorders. Praxis plans to initiate a Phase 2 clinical trial in the first half of 2022 to explore the potential for PRAX-562 to treat a range of rare pediatric DEEs, including SCN2A-DEE and SCN8A-DEE. PRAX-562 is currently being evaluated in a Phase 1 clinical trial in adult healthy volunteers.

ShowHide Related Items >><<
PRAX Praxis Precision Medicines
$32.15 /

+0.32 (+1.01%)

PRAX Praxis Precision Medicines
$32.15 /

+0.32 (+1.01%)

04/26/21 William Blair
Praxis Precision Medicines initiated with an Outperform at William Blair
04/16/21 Piper Sandler
Praxis Precision Medicines transferred with Overweight at Piper Sandler
03/17/21 Piper Sandler
Piper sees 114 IND, pivotal trial as sign of Praxis regulatory capabilities
01/21/21 Wedbush
Praxis Precision Medicines price target raised to $61 from $51 at Wedbush
PRAX Praxis Precision Medicines
$32.15 /

+0.32 (+1.01%)

  • 16
    Oct
PRAX Praxis Precision Medicines
$32.15 /

+0.32 (+1.01%)

Hot Stocks
Praxis Precision Medicines appoints Merit Cudkowicz to board of directors » 08:20
04/29/21
04/29
08:20
04/29/21
08:20
PRAX

Praxis Precision Medicines

$31.65 /

+1.54 (+5.11%)

Praxis Precision…

Praxis Precision Medicines announced the appointment of Merit Cudkowicz, M.D., to its board of directors. Cudkowicz is the chief of neurology at Mass General Hospital, director of the Sean M. Healey & AMG Center for ALS, and director and the Julieanne Dorn professor of neurology at Harvard Medical School.

ShowHide Related Items >><<
PRAX Praxis Precision Medicines
$31.65 /

+1.54 (+5.11%)

PRAX Praxis Precision Medicines
$31.65 /

+1.54 (+5.11%)

04/26/21 William Blair
Praxis Precision Medicines initiated with an Outperform at William Blair
04/16/21 Piper Sandler
Praxis Precision Medicines transferred with Overweight at Piper Sandler
03/17/21 Piper Sandler
Piper sees 114 IND, pivotal trial as sign of Praxis regulatory capabilities
01/21/21 Wedbush
Praxis Precision Medicines price target raised to $61 from $51 at Wedbush
PRAX Praxis Precision Medicines
$31.65 /

+1.54 (+5.11%)

  • 16
    Oct
PRAX Praxis Precision Medicines
$31.65 /

+1.54 (+5.11%)

Hot Stocks
Praxis Precision Medicines gets FDA designation in SCN2A Encephalopathy » 06:31
04/28/21
04/28
06:31
04/28/21
06:31
PRAX

Praxis Precision Medicines

$30.11 /

-0.97 (-3.12%)

Praxis Precision…

Praxis Precision Medicines received orphan drug designation from the FDA for the treatment of SCN2A Developmental and Epileptic Encephalopathy. Reference Link

ShowHide Related Items >><<
PRAX Praxis Precision Medicines
$30.11 /

-0.97 (-3.12%)

PRAX Praxis Precision Medicines
$30.11 /

-0.97 (-3.12%)

04/26/21 William Blair
Praxis Precision Medicines initiated with an Outperform at William Blair
04/16/21 Piper Sandler
Praxis Precision Medicines transferred with Overweight at Piper Sandler
03/17/21 Piper Sandler
Piper sees 114 IND, pivotal trial as sign of Praxis regulatory capabilities
01/21/21 Wedbush
Praxis Precision Medicines price target raised to $61 from $51 at Wedbush
PRAX Praxis Precision Medicines
$30.11 /

-0.97 (-3.12%)

  • 16
    Oct
PRAX Praxis Precision Medicines
$30.11 /

-0.97 (-3.12%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.